background
middl
east
respiratori
syndrom
coronaviru
merscov
infect
associ
high
mortal
approv
antivir
therapi
aim
compar
ribavirin
interferon
treatment
patient
sever
merscov
infect
support
therapi
method
retrospect
cohort
studi
includ
adult
age
year
laboratoryconfi
rmed
merscov
infect
pneumonia
need
ventil
support
diagnos
oct
may
princ
sultan
militari
medic
citi
riyadh
saudi
arabia
patient
receiv
appropri
support
care
regular
clinic
laboratori
monitor
patient
diagnos
sept
also
given
oral
ribavirin
dose
base
calcul
creatinin
clearanc
day
subcutan
pegyl
interferon
per
week
week
primari
endpoint
surviv
date
merscov
infect
diagnosi
use
fischer
exact
test
analys
categor
variabl
test
analys
continu
variabl
similar
group
apart
baselin
absolut
neutrophil
count
signifi
cantli
lower
compar
group
sd
vs
patient
treatment
group
surviv
day
compar
seven
compar
group
day
six
four
respect
surviv
advers
eff
ect
similar
group
apart
reduct
haemoglobin
signifi
cantli
greater
treatment
group
compar
group
gl
sd
vs
gl
interpret
patient
sever
merscov
infect
ribavirin
interferon
therapi
associ
signifi
cantli
improv
surviv
day
day
assess
appropri
design
randomis
trial
recommend
sinc
fi
rst
describ
septemb
case
middl
east
respiratori
syndrom
coronaviru
merscov
infect
confi
rmed
fatal
case
occur
sporad
commun
cluster
hospit
outbreak
rang
sever
asymptomat
mild
ill
rapidli
progress
fatal
diseas
manag
patient
merscov
infect
consist
combin
support
measur
antimicrobi
therapi
associ
bacteri
viral
infect
strict
implement
appropri
infect
control
precaut
far
antivir
therapi
approv
treatment
patient
merscov
infect
sever
therapeut
intervent
coronaviru
investig
larg
multin
outbreak
sever
acut
respiratori
syndrom
sar
review
avail
scientifi
c
literatur
suggest
combin
ribavirin
interferon
might
benefi
patient
sever
merscov
infect
furthermor
combin
shown
inhibit
merscov
cell
cultur
seem
improv
outcom
anim
studi
agent
associ
substanti
potenti
advers
eff
ect
henc
clinic
use
care
balanc
potenti
harm
aim
assess
outcom
treatment
programm
patient
sever
merscov
infect
consist
oral
ribavirin
subcutan
pegyl
interferon
report
result
outcom
patient
given
treatment
accord
protocol
comparison
histor
group
receiv
support
therapi
singlecentr
retrospect
cohort
studi
includ
individu
diagnos
laboratoryconfi
rmed
merscov
infect
oct
may
princ
sultan
militari
medic
citi
riyadh
saudi
arabia
elig
patient
age
year
older
sever
pneumonia
need
invas
noninvas
ventil
exclus
criteria
appli
stage
merscov
infect
diagnos
rtpcr
test
respiratori
tract
sampl
merscov
upe
orf
n
gene
rtpcr
test
merscov
done
saudi
ministri
health
region
laboratori
jeddah
riyadh
saudi
arabia
pneumonia
defi
ned
new
otherwis
unexplain
lower
respiratori
tract
symptom
cough
short
breath
least
one
system
featur
fever
chill
new
focal
chest
sign
examin
addit
new
progress
pulmonari
infi
ltrate
chest
radiograph
sept
elig
patient
ere
treatment
oral
ribavirin
subcutan
pegyl
interferon
inform
written
consent
obtain
patient
next
kin
treatment
protocol
approv
pharmaci
therapeut
committe
studi
approv
research
ethic
committe
princ
sultan
militari
medic
citi
allow
retrospect
access
patient
record
fi
le
pegyl
interferon
pegasi
roch
pharmaceut
basel
switzerland
given
subcutan
inject
dose
per
week
week
dose
oral
ribavirin
copegu
roch
pharmaceut
adjust
accord
calcul
creatinin
clearanc
continu
day
patient
creatinin
clearanc
greater
mlsecm
receiv
mg
load
dose
follow
mg
everi
h
day
mg
everi
h
day
creatinin
clearanc
receiv
mg
load
dose
follow
mg
everi
h
day
mg
everi
h
day
creatinin
clearanc
dialysi
receiv
mg
load
dose
follow
mg
everi
h
day
mg
everi
h
day
patient
receiv
ribavirin
interferon
therapi
diagnos
sept
declin
consent
patient
receiv
appropri
support
care
supplementari
oxygen
vasopressor
therapi
renal
replac
need
hydrocortison
mg
daili
given
patient
refractori
septic
shock
continu
vasopressor
therapi
longer
need
addit
regular
clinic
monitor
renal
function
liver
enzym
blood
count
assess
baselin
daili
throughout
treatment
cours
consciou
patient
monitor
clinic
sign
depress
acut
confus
patient
receiv
ribavirin
interferon
therapi
classifi
ed
treatment
group
made
compar
group
two
investig
aso
kb
mask
group
alloc
patient
clinic
outcom
compar
baselin
characterist
two
group
immunosuppress
therapi
data
number
mean
sd
apach
iiacut
physiolog
chronic
health
evalu
ii
sofasequenti
organ
failur
assess
patient
assess
patient
assess
patient
assess
primari
endpoint
studi
surviv
date
merscov
infect
diagnosi
use
fischer
exact
test
categor
variabl
wherea
use
student
test
continu
variabl
assess
diff
erenc
mean
two
group
logrank
test
use
assess
surviv
diff
erenc
two
group
cutoff
statist
signifi
canc
graphic
statist
test
suggest
pro
portionalhazard
assumpt
violat
statist
analys
use
microsoft
excel
stata
statist
softwar
releas
extern
fund
receiv
studi
zm
full
access
data
studi
fi
nal
respons
decis
submit
public
individu
diagnos
merscov
infect
oct
may
baselin
characterist
gener
similar
patient
receiv
ribavirin
interferon
therapi
tabl
except
endstag
renal
failur
present
three
patient
receiv
studi
treatment
none
exclud
inelig
patient
patient
includ
studi
treatment
group
compar
group
fi
gure
mean
age
patient
year
sd
men
tabl
mean
absolut
neutrophil
count
signifi
cantli
lower
treatment
group
compar
group
tabl
howev
statist
signifi
cant
differ
baselin
characterist
support
measur
note
two
group
tabl
patient
still
aliv
day
diagnosi
merscov
infect
wherea
day
ten
surviv
patient
treatment
group
aliv
day
diagnosi
compar
seven
compar
group
howev
six
patient
treatment
group
surviv
day
diagnosi
merscov
infect
wherea
four
compar
group
fi
gure
ribavirin
pegyl
interferon
therapi
well
toler
treatment
group
prematur
discontinu
secondari
advers
eff
ect
howev
mean
drop
haemoglobin
treatment
cours
signifi
cantli
greater
treatment
group
gl
sd
compar
group
eff
ectiv
treatment
intervent
patient
sever
merscov
infect
still
urgent
need
critic
ill
patient
sever
merscov
infect
studi
show
ribavirin
pegyl
interferon
therapi
associ
signifi
cant
surviv
benefi
compar
standard
treatment
surviv
also
seem
improv
ribavirin
pegyl
interferon
therapi
diff
erenc
group
signifi
cant
panel
loss
signifi
cant
surviv
diff
erenc
time
might
partli
explain
patient
cohort
sever
comorbid
high
apach
ii
sofa
score
mortal
known
high
patient
sever
merscov
infect
need
criticalcar
support
therefor
longterm
surviv
benefi
present
might
diffi
cult
show
smaller
studi
treatment
ribavirin
interferon
well
toler
studi
advers
event
signifi
cantli
wors
treatment
group
mean
decreas
haemoglobin
gl
treatment
group
compar
gl
compar
group
anaemia
well
recognis
complic
ribavirin
therapi
note
previous
studi
investig
role
ribavirin
treatment
sar
coronaviru
infect
note
receipt
pack
red
blood
cell
signifi
cantli
diff
erent
treatment
compar
group
studi
furthermor
treatment
discontinu
occur
result
anaemia
therefor
risk
ribavirinassoci
anaemiaalthough
substanti
need
care
monitoringmight
hinder
use
ribavirin
patient
sever
merscov
infect
especi
surviv
benefi
confi
rmed
baselin
absolut
neutrophil
count
signifi
cantli
lower
treatment
group
therefor
signifi
cantli
lower
minim
absolut
neutrophil
count
cours
ill
surpris
sever
investig
show
interferon
use
invitro
activ
merscov
howev
compar
interferon
interferon
interferon
seem
potent
inhibitori
invitro
activ
merscov
ribavirin
slight
antimerscov
activ
vitro
use
alon
combin
interferon
mycophenol
acid
anoth
compound
exhibit
signifi
cant
invitro
activ
merscov
compound
screen
activ
cell
cultur
merscov
although
combin
interferon
plu
ribavirin
far
undergon
invivo
assess
ment
merscov
mani
other
potenti
candid
clinic
assess
one
limit
studi
small
size
howev
two
previou
report
clinic
use
ribavirin
interferon
merscov
infect
publish
retrospect
report
fi
patient
sever
merscov
infect
signifi
cant
comorbid
need
mechan
ventil
receiv
com
binat
ribavirin
pegyl
interferon
median
day
admiss
none
patient
surviv
investig
conclud
late
commenc
therapi
might
benefi
cial
anoth
report
patient
sever
merscov
infect
receiv
ribavirin
interferon
therapi
good
clinic
respons
signifi
cant
advers
eff
ect
studi
albeit
small
largest
clinic
investig
far
assess
use
combin
treatment
patient
sever
merscov
infect
although
baselin
characterist
treatment
compar
group
seem
reason
balanc
substanti
diff
erenc
might
appar
small
number
patient
studi
studi
also
limit
retrospect
nonrandomis
natur
inevit
select
unmeasur
confound
bia
complet
exclud
undoubtedli
new
intervent
ideal
assess
randomis
control
clinic
trial
howev
approach
gener
accept
alway
practic
feasibl
context
emerg
rel
uncommon
diseas
merscov
infect
care
select
compar
group
ensur
two
cohort
match
close
possibl
clinic
characterist
treatment
intervent
receipt
ribavirin
interferon
remov
three
individu
outli
baselin
serum
creatinin
compar
group
minimis
risk
spuriou
conclus
driven
clinic
characterist
might
potenti
detriment
clinic
outcom
clinic
outcom
individu
mask
investig
select
patient
match
assess
absenc
serial
viral
load
measur
lower
respiratori
tract
sampl
studi
make
imposs
show
associ
tempor
viral
load
chang
antivir
therapi
measur
includ
futur
clinic
studi
explor
therapeut
benefi
antivir
intervent
patient
merscov
infect
sever
merscov
associ
poor
overal
surviv
treatment
oral
ribavirin
subcutan
pegyl
interferon
associ
signifi
cantli
improv
surviv
day
day
combin
associ
signifi
cant
fall
haemoglobin
signifi
cant
advers
eff
ect
note
treatment
ribavirin
pegyl
interferon
might
consid
patient
sever
merscov
infect
provid
adequ
monitor
assess
ensur
assess
includ
patient
less
sever
merscov
infect
appropri
design
randomis
trial
recommend
studi
initi
design
aso
mm
zam
ama
aso
mm
ab
mam
aya
gaa
mma
zam
ama
obtain
collat
patient
data
kb
undertook
statist
analys
studi
aso
kb
prepar
tabl
fi
gure
aso
mm
zam
ama
wrote
fi
rst
draft
manuscript
author
review
contribut
subsequ
draft
fi
nal
report
aso
receiv
consult
fee
gilead
pfi
zer
msd
viiv
payment
lectur
pfi
zer
msd
glaxosmithklin
sanofi
aventi
sponsorship
attend
intern
meet
confer
msd
pfi
zer
biopharma
bristolmy
squibb
janssencilag
ab
receiv
travel
fund
attend
intern
meet
pfi
zer
gaa
receiv
travel
fund
attend
intern
meet
edward
lifesci
author
declar
compet
interest
